Kenvue Announces Launch of Secondary Offering
13 Maggio 2024 - 12:46PM
Business Wire
Kenvue Inc. (NYSE: KVUE) (“Kenvue”) announced today the launch
of a secondary underwritten public offering (the “Offering”) of
182,329,550 shares of its common stock (the “Shares”). Kenvue is
not selling any shares of common stock and will not receive any
proceeds from the sale of the Shares in the Offering or from the
debt-for-equity exchange (as described below).
In connection with the Offering, Johnson & Johnson (NYSE:
JNJ) is expected to exchange 182,329,550 shares of Kenvue’s common
stock for indebtedness of Johnson & Johnson expected to be held
by Goldman Sachs & Co. LLC and J.P. Morgan (collectively, the
“Selling Shareholders”). Following the debt-for-equity exchange, if
consummated, the Selling Shareholders intend to sell the Shares to
the underwriters in the Offering. After the completion of the
proposed Offering, Johnson & Johnson will no longer own any
shares of Kenvue’s common stock.
Goldman Sachs & Co. LLC, J.P. Morgan and BofA Securities are
acting as joint lead book-running managers for the Offering.
A registration statement on Form S-1 relating to these
securities has been filed with the Securities and Exchange
Commission but has not yet become effective. These securities may
not be sold, nor may offers to buy be accepted, prior to the time
the registration statement becomes effective. The Offering will be
made only by means of a prospectus. A copy of the preliminary
prospectus relating to the Offering may be obtained from Goldman
Sachs & Co. LLC, Attention: Prospectus Department, 200 West
Street, New York, New York 10282, telephone: 1-866-471-2526,
facsimile: 212-902-9316, or by emailing:
prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
New York 11717 or by emailing: prospectus-eq_fi@jpmchase.com and
postsalemanualrequests@broadridge.com; or BofA Securities,
NC1-022-02-25, Attention: Prospectus Department, 201 North Tryon
Street, Charlotte, North Carolina 28255, telephone: 1-800-294-1322,
or by emailing: dg.prospectus_requests@bofa.com.
This press release is neither an offer to sell nor a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such an offer, solicitation or sale would be unlawful.
About Kenvue
Kenvue is the world’s largest pure-play consumer health company
by revenue. Built on more than a century of heritage, our iconic
brands, including Aveeno®, BAND-AID® Brand, Johnson’s®, Listerine®,
Neutrogena®, and Tylenol®, are science-backed and recommended by
healthcare professionals around the world. At Kenvue, we believe in
the extraordinary power of everyday care and our teams work every
day to put that power in consumers’ hands and earn a place in their
hearts and homes.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as
defined in the Private Securities Litigation Reform Act of 1995
regarding, among other things, statements about the timing and
details of the Offering, the Selling Shareholders’ intent to offer
the shares of common stock and the number of shares of Kenvue’s
common stock to be held by Johnson & Johnson following the
Offering. Forward-looking statements may be identified by the use
of words such as “plans,” “expects,” “will,” “anticipates,”
“estimates” and other words of similar meaning. Readers are
cautioned not to rely on these forward-looking statements. These
statements are based on current expectations of future events. If
underlying assumptions prove inaccurate or known or unknown risks
or uncertainties materialize, actual results could vary materially
from the expectations and projections of Kenvue and its
affiliates.
A list and descriptions of risks, uncertainties and other
factors can be found in Kenvue’s filings with the Securities and
Exchange Commission, including its registration statement on Form
S-1, Annual Report on Form 10-K and subsequent Quarterly Reports on
Form 10-Q and other filings, available on request from Kenvue.
Kenvue and its affiliates undertake no obligation to update any
forward-looking statements, whether as a result of new information,
future events or developments or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240512848045/en/
Investor Relations: Tina Romani (Kenvue)
Kenvue_IR@kenvue.com
Grafico Azioni Kenvue (NYSE:KVUE)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Kenvue (NYSE:KVUE)
Storico
Da Giu 2023 a Giu 2024